A股異動丨萬豐奧威(002085.SZ)漲4.36% 獲得特斯拉配套商定點項目
格隆匯6月29日丨萬豐奧威(002085.SZ)漲4.36%,報6.7元,總市值146.5億元。萬豐奧威昨日公佈,公司收到控股子公司上海鎂鎂合金壓鑄有限公司和無錫雄偉精工科技有限公司的通知,上海鎂鎂近日獲得佛吉亞中國(佛吉亞中國為特斯拉一級供應商,為其ModelY配套座椅)鎂合金座椅支架定點函,項目訂單金額約5,000萬元。無錫雄偉獲得延鋒安道拓(延鋒安道拓為特斯拉一級供應商,為其ModelY配套座椅骨架)座椅骨架衝壓件定點函,項目訂單金額約7,000萬元。截止目前,公司已獲得特斯拉項目定點金額總計達3億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.